| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba45573cde21364d017c4c457dae1152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2018-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc8d21cdfb82f8f6f5e2b5f8588724f |
| publicationDate |
2019-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019083904-A1 |
| titleOfInvention |
AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF |
| abstract |
The present invention relates to methods for determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods for monitoring and / or treating a subject suffering from an acute flavivirus infection and / or who is at risk of progression of a clinically significant infection or disease. This level can also be used in a vaccination process to ensure that those receiving a flavivirus vaccine have a reduced risk of vaccine response to developing a clinically significant infection or disease. The invention also provides methods of treatment based on inhibition of FcγRIIA or FcγRIIIA receptor signaling. The invention also relates to novel cell lines which are useful in the measurement of afucosylated Fc glycans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021231304-A1 |
| priorityDate |
2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |